show the much larger inertia of this part of the climate system. The LOW GEO option and WRE450 scenario again are similar, with neither tending toward stabiliza
tion. Even the HIGH GEO option shows a continuing (but slow) rise in sea level toward the end of the study period, but the rate of rise is small, even relative to changes observed over the 20th century (30, 32) .
A combined mitigation/geoengineering approach to climate stabilization has a number of advantages over either alternative used separately. A relatively modest geoengineering investment (33, 34) corresponding to the present LOW GEO option could reduce the economic and technological burden on mitigation substantially, by deferring the need for immediate or near-future cuts in CO 2 emissions. More ambitious geoengineering, when combined with mitigation, could even lead to the stabilization of global mean temperature at near present levels and reduce future sea-level rise to a rate much less than that observed over the 20th century: aspects of future change that are virtually impossible to achieve through mitigation alone.
As a guide to the amount of SO 2 required, the eruption of Mount Pinatubo injected about 10 teragrams of sulfur (TgS) into the stratosphere (35, 36) , and the analysis here suggests that an annual flux of half that amount would have a substantial influence. Smaller diameter aerosols would have longer lifetimes and require still smaller injection rates (15) . Five TgS/year is only È7% of current SO 2 emissions from fossil fuel combustion (37, 38) . Further analysis is required to assess (i) the technological feasibility of the suggested injections of SO 2 Eor of more radiatively efficient material (34) ^into the stratosphere, (ii) the economic costs of this option relative to the reduced costs of mitigation that an overshoot CO 2 -stabilization pathway would allow, and (iii) the detailed effects of the proposed SO 2 injections and CO 2 concentration changes on climate Ecompare with (39) An effective host immune response to mycobacterial infection must control pathogen dissemination without inducing immunopathology. Constitutive overexpression of mycobacterial heat shock protein (myHsp70) is associated with impaired bacterial persistence, but the immune-mediated mechanisms are unknown. We found that myHsp70, in addition to enhancing antigen delivery to human dendritic cells, signaled through the CCR5 chemokine receptor, promoting dendritic cell aggregation, immune synapse formation between dendritic cells and T cells, and the generation of effector immune responses. Thus, CCR5 acts as a pattern-recognition receptor for myHsp70, which may have implications for both the pathophysiology of tuberculosis and the use of myHsps in tumor-directed immunotherapy.
M ycobacterium tuberculosis infects one-third of the world_s population and is responsible for two million deaths annually. A tightly controlled T cell response to M. tuberculosis results in granuloma formation, which limits mycobacterial replication and controls the immunopathological consequences of infection (1) . The immune response and granuloma formation are regulated by host and mycobacterial factors (2); one of these, mycobacterial heat shock protein 70 (myHsp70), stimulates dendritic cells (DCs) to release proinflammatory mediators (3) . Hsps are conserved between microorganisms and mammalian cells and have a well-characterized role in protein assembly (4) . Their ability to bind and deliver short polypeptides to immature dendritic cells (iDCs) is being exploited in tumor-directed DC immunotherapy (5) . Picomolar concentrations of peptide bound to myHsp70 can generate antigen-specific cytotoxic T lymphocyte (CTL) responses through efficient peptide delivery and direct iDC stimulation by myHsp70 (6) . A calcium-dependent intracellular signaling cascade triggered by myHsp70, but not by Tolllike receptor (TLR) agonists (6) , is critical for the generation of effector immune responses, but neither the surface receptor nor the cellular mechanisms involved are known.
To further characterize the myHsp70-mediated calcium signal in iDCs, we demonstrated that pertussis toxin, an inhibitor of heterotrimeric G-protein-coupled receptor (GPCR) transduction, inhibited signaling of both myHsp70 and the control GPCR-mediated agonist, N-formyl-MetLeu-Phe (fMLP; Fig. 1A ). Analysis of potential GPCRs expressed on iDCs, using a heterologous expression system, revealed that myHsp70 signaled through a CC chemokine receptor. We examined glioma cells expressing different chemokine receptors and found that myHsp70 triggered a calcium response in cells expressing CCR5, and to a much lesser extent CCR1 (Fig. 1B) . Alexa488-conjugated myHsp70 showed specific binding to After the removal of unbound cells, iDCs were labeled with antibody to major histocompatibility complex II (anti-HLA-DR) (red) and CD8 T cells were labeled with anti-CD3 (green); cells were then examined by confocal microscopy. (B) T cells associated with each iDC were quantified 30 min after the addition of myHsp70, myHsp70 after preincubation with BAPTA-AM, LPS (100 ng/ml), or BSA control. (C) myHsp70-induced formation of DC-T cell contacts was analyzed by simultaneous fluorescence and DIC imaging of Fluo3-labeled iDCs with CD4 or CD8 T cells (unlabeled) after the addition of myHsp70 (200 nM), using cells from CCR5 wild-type or CCR5D32 homozygotes. Contact between myHsp70-stimulated iDCs and T cells was reduced in the absence of functional CCR5 on iDCs.
CCR5-expressing but not control CXCR4-expressing cells (Fig. 1C) and was inhibited by competition with unlabeled myHsp70 (Fig. 1C) . CCR5-dependent signaling also occurred in primary human DCs, because the CCR5 antagonist TAK-779 (7) inhibited calcium signaling in iDCs triggered by myHsp70 and the endogenous CCR5 ligand, MIP-1b, but not calcium signaling by fMLP (Fig. 1D) .
The requirement for CCR5 in myHsp70 signaling was confirmed by examining calcium responses in iDCs from a donor homozygous for the CCR5D32 allele, the naturally occurring 32-nucleotide deletion that prevents CCR5 surface expression (8) (Fig. 1E and fig. S1 ). The absence of myHsp70-or MIP-1b-mediated calcium signaling in CCR5D32 iDCs confirmed an absolute requirement for CCR5 in this pathway (Fig.  1E) . A dose-response comparison of calcium signals in iDCs showed MIP-1b to be five times more potent than myHsp70 (Fig. 1F) . A lysate from M. bovis bacille Calmette Gu2rin (BCG) also triggered a TAK-779-inhibitable calcium signal, suggesting that sufficient myHsp70 is present to promote CCR5-dependent signaling (Fig. 1G) . Furthermore, CCR5-dependent myHsp70 signaling was species-specific, because no myHsp70 signal was seen in CCR5-expressing mouse macrophages (Fig. 1H) , myHsp70 did not involve TLR signaling pathways Eas assessed by microarray analysis ( fig.  S2A and table S1) and assays of nuclear factor kB activity ( fig. S2 , B and C)^, and myHsp70 induces a calcium-dependent phenotypic maturation of DCs (fig. S3) .
The immediate morphological consequences of CCR5-mediated Hsp70 calcium signaling were further investigated by live cell imaging of iDCs (Fig. 2, A to C, and video S1 ). The addition of myHsp70 triggered calcium oscillations, immediately followed by rapid cell membrane ruffling and pseudopodia projection (Fig. 2C) . Correlation of intracellular calcium oscillations with cell movement, by means of simultaneous fluorescence differential interference contrast (DIC) imaging, suggested that a rise in intracellular calcium was required, but not sufficient, to trigger membrane changes and cell aggregation. Membrane changes and cell aggregation were inhibited by chelation of intracellular calcium and could not be induced by calcium rises induced by adenosine triphosphate (ATP) or phorbol myristate acetate/ionomycin (Fig. 2D and fig. S4 ). These morphological changes were also mediated through CCR5. They were inhibited by TAK-779, were not seen in DCs from CCR5D32 homozygotes (Fig. 2D) , and were not induced by TLR agonists (Fig.  2D) . Thus, myHsp70 stimulation of human DCs results in rapid CCR5-mediated, calciumdependent, nonrandom migration of iDCs and the projection of plasma membrane extensions.
To examine how myHsp70 affected interactions between DCs and T cells, we stimulated iDCs and autologous T cells with myHsp70. Autologous T cells rapidly clustered around the DCs (Fig. 3A) . More T cells (up to nine) associated with each DC after stimulation with myHsp70 than with bovine serum albumin (BSA) or lipopolysaccharide (LPS), and this enhanced interaction was inhibited by 1,2-bis(oaminophenoxy)ethane-N,N,N ¶ ,N ¶-tetraacetic acid (BAPTA) preloading (Fig. 3B) . The trapping of T cells by DCs was observed as early as 30 s after stimulation of iDCs ( Fig. 3C and videos S2 and S3), was facilitated by the formation of a network of DC membrane extensions (Fig. 3C) , and was seen with both autologous and allogeneic CD4 and CD8 T cells (Fig. 3C) . The formation of the membrane extensions and T cell clusters was dependent on functional CCR5 receptors on DCs but not on T cells (Fig. 3C and video S4) . The rapid clustering of DCs and associated T cells suggested an integrin-mediated mechanism. The addition of myHsp70 led to a rapid increase in b 2 -integrin-specific iDC binding to immobilized intercellular adhesion molecule-2 (ICAM-2), ICAM-3, and (to a lesser extent) ICAM-1 (Fig.  4A) (9) . This rapid T cell trapping by DCs stimulated with myHsp70 was followed at later time points (after 30 min) by T cell polarization of talin and LFA-1 toward the point of contact with the DC (Fig. 4B) , suggesting the formation of antigen-independent immune synapses (10, 11) . The ability of myHsp70 to promote iDC-T cell interactions may explain why T cells are required for myHsp70 to stimulate pro-inflammatory cytokine release from DCs ( fig. S5) (6) .
CCR5 mediated a number of functional consequences of myHsp70 signaling. myHsp70 and the CCR5 agonist RANTES induced interleukin-6 (IL-6) release from wild-type but not CCR5D32 iDCs (Fig. 4C) . Furthermore, pretreatment of iDCs with pertussis toxin or TAK-779 inhibited the ability of peptide-loaded myHsp70 to stimulate DCs to generate influenza peptide-specific CTLs (Fig. 4D) . To examine the effect of CCR5-mediated signaling in mycobacterial infection, we used the model pathogen M. bovis BCG-lux (12) . As reported for murine DCs (13), human DCs from immune people were unable to kill internalized mycobacteria, even in the presence of autologous T cells. TAK-779 inhibition of CCR5 led to a dose-dependent enhancement of intracellular mycobacterial replication (Fig. 4E and fig.  S6A ) at all concentrations of mycobacteria tested ( fig. S6B) , suggesting an important role for this receptor in controlling mycobacterial infection.
The identification of CCR5 as the critical receptor for myHsp70-mediated DC stimulation has implications for both mycobacterial infection and the therapeutic use of myHsp70. CCR5 is important in immune cell cross talk. Interaction with its naturally occurring ligand MIP-1b promotes the recruitment of cells to sites of inflammation (14), facilitates immune synapse formation (15) , orchestrates T cell interactions within lymph nodes (16) , and controls the activation and differentiation of T cells (17) . Our finding that a mycobacterial lysate, as well as purified myHsp70, stimulated a CCR5-dependent calcium response indicates a further connection between the innate and adaptive immune responses during mycobacterial infection. The cellular aggregation induced by myHsp70 signaling through CCR5 may play an important role in the formation of granulomas, the hallmark of mycobacterial infection.
Microbial-induced DC responses need to be highly regulated, reflecting a balance between a rapid and appropriate response to invading microbes and the inducement of immunopathology (2)-a particular problem in mycobacterial infection. An increasing number of human pathogens, including HIV (18), toxoplasma (19) , and M. tuberculosis (as described here), target the CCR5 receptor. This role of CCR5 as a patternrecognition receptor for myHsp70 may, at least in part, be responsible for the maintenance of the high CCR5D32 allele frequency (10 to 15%) in Northern European populations (20) and may alter the pattern of disease seen in people with the CCR5D32 allele. The role of constraint in adaptive evolution is an open question. Directed evolution of an engineered b-isopropylmalate dehydrogenase (IMDH), with coenzyme specificity switched from nicotinamide adenine dinucleotide (NAD) to nicotinamide adenine dinucleotide phosphate (NADP), always produces mutants with lower affinities for NADP. This result is the correlated response to selection for relief from inhibition by NADPH (the reduced form of NADP) expected of an adaptive landscape subject to three enzymatic constraints: an upper limit to the rate of maximum turnover (k cat ), a correlation in NADP and NADPH affinities, and a trade-off between NAD and NADP usage. Two additional constraints, high intracellular NADPH abundance and the cost of compensatory protein synthesis, have ensured the conserved use of NAD by IMDH throughout evolution. Our results show that selective mechanisms and evolutionary constraints are to be understood in terms of underlying adaptive landscapes.
T he old notion of natural selection as an omnipotent force in biological evolution has given way to one where adaptive processes are constrained by physical, chemical, and biological exigencies (1) (2) (3) (4) . Whether constraint and/or stabilizing selection explain phenotypic stasis, in the fossil record and in phylogenies, remains an open question (5) . Direct experimental tests of constraint are scarce (6) (7) (8) (9) . Even tight correlations among traits, at once suggestive of constraint, can be broken by artificial selection to produce new phenotypic combinations (8, 9) . Despite all circumstantial evidence, results from direct experimental tests imply that selection is largely unconstrained.
The direct experimental test for constraint is conceptually simple. A phenotype is subjected to selection (natural or artificial) in an attempt to break the postulated constraint (6) (7) (8) (9) . A response to selection indicates a lack of constraint. No response to selection indicates the presence of a constraint. However, the cause of a constraint is rarely specified because the etiologies of most phenotypes are not well understood, their relationships to fitness are usually opaque, and a lack of response to selection may reflect nothing more than a lack of heritable variation (4, 7) . If the cause of a constraint is to be elucidated, it must be for a simple phenotype whose relationship to fitness is understood.
Coenzyme use by b-isopropylmalate dehydrogenase (IMDH) is a simple phenotype whose etiology and relationship to fitness are understood (10, 11) . IMDHs catalyze the oxidative decarboxylation of b-isopropylmalate to a-ketoisocaproate during the biosynthesis of leucine, an essential amino acid. All IMDHs use nicotinamide adenine dinucleotide (NAD) as a coenzyme (cosubstrate). This invariance of function among IMDHs hints at the presence of ancient constraints, even though some related isocitrate dehydrogenases (IDHs) use NADP instead (12, 13) .
Structural comparisons with related NADPusing IDHs identify amino acids controlling coenzyme use (14) (15) (16) (Fig. 1A) 
